UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 25,

2007

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17

CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 5.02

Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers

On October 25, 2007, the Company issued a press release announcing that,

after a 31-year career, Vice Chairman David L. Shedlarz will retire from

Pfizer at the end of 2007. The information contained in the press release

is deemed to be "filed" under the Securities Exchange Act of

1934 as Exhibit 99 to this report and is incorporated herein by reference.

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change

in Fiscal Year

On October 25, 2007, the Board of Directors approved an amendment to

Article I, Section 5 of the Company's bylaws to change the vote standard

for the election of directors from plurality to a majority of votes cast

in uncontested elections. A majority of the votes cast means that the

number of votes cast "for" a director must exceed the number

of votes cast "against" that director. In contested elections

the vote standard will continue to be a plurality of votes cast. In addition,

the Board approved an amendment to Article II, Section 13 of the bylaws

to provide that director nominees proposed by shareholders must deliver

a statement that, if elected, they agree to tender an irrevocable resignation,

in accordance with the Company s Corporate Governance Principles

that are applicable to all director nominees, upon failure to receive

the required vote in a subsequent election.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

3.1

Pfizer Inc. By-laws, as amended on October 25,

2007

99

Press Release of Pfizer Inc. dated October 25,

2007, announcing the retirement of Vice Chairman David L. Shedlarz at the

end of 2007. Exhibit 99 is deemed to be "filed" under the Securities

Exchange Act of 1934 in this Current Report on Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate

Governance, Associate General Counsel and Corporate Secretary

Dated: October 30, 2007

EXHIBIT INDEX

Exhibit No.

Description

3.1

Pfizer Inc. By-laws, as amended on October 25, 2007

99

Press Release of Pfizer Inc. dated October 25, 2007, announcing the retirement

of Vice Chairman David L. Shedlarz at the end of 2007. Exhibit 99 is deemed

to be "filed" under the Securities Exchange Act of 1934 in this

Current Report on Form 8-K.